{
Gilead Sciences, Inc.

Companies

}
Symbol GILD
Name Gilead Sciences, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Pharmaceuticals
Market NASDAQ Global Select
Country United States
State CA
City Foster City
Zipcode 94404
Website http://www.gilead.com
Track all markets on TradingView
Novartis to close MorphoSys sites and lay off 330 employees
Novartis is closing MorphoSys sites in Munich and Boston, resulting in approximately 330 layoffs, as part of its integration strategy following the €2.7 billion acquisition earlier this year. The decision aligns with a focus on prioritizing R&D programs, particularly the delayed approval pathway for the oncology candidate pelabresib. This trend of post-acquisition job cuts has been observed across several major pharma companies in recent years.
Fierce Pharma
Euro Sanofi GSK plc Gilead Sciences, Inc. Incyte Corp Novartis AG Immunomedics Inc. Horizon Therapeutics Public Lim Bellus Health Inc. Merck & Co., Inc. Bristol-Myers Squibb Co Amgen Inc. MorphoSys AG USA DEU CHE Vas Narasimhan Show more
Finance & Economy, News Article
15:47 19.12.2024
Roche secures EU approval for Vabysmo prefilled syringe for retinal diseases
Roche has received EU approval for a prefilled syringe (PFS) of its ophthalmology drug Vabysmo, designed to treat neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. This PFS offers a convenient administration method for over 9 million affected individuals in the EU and is the first of its kind containing a bispecific antibody for these conditions. Following strong sales growth, the approval is expected to further enhance Roche's revenue amid increasing competition in the ophthalmology market.
Yahoo Finance
Swiss Franc Bristol-Myers Squibb Co Regeneron Pharmaceuticals, Inc. Hoffmann-La Roche AG Gilead Sciences, Inc. CHE Show more
Healthcare, Market Report
19:40 16.12.2024
setbacks in drug development impact schizophrenia and oncology markets
AbbVie's schizophrenia drug emraclidine failed two mid-phase trials, performing no better than placebo, resulting in a $40 billion market cap loss for the company. This setback follows the recent approval of Bristol Myers Squibb's Cobenfy, the first new schizophrenia drug in decades, which boosted BMS's share price by 12%. The failure raises concerns for other companies developing similar drugs in the same class.
PharmaVoice
Arcus Biosciences, Inc. Hoffmann-La Roche AG Gilead Sciences, Inc. Biohaven Ltd. Merck & Co., Inc. Genentech Cassava Sciences, Inc. ABBVIE Bristol-Myers Squibb Co BioAge Labs, Inc. USA Jean Rochefort Show more
Finance & Economy, Market Report
01:00 16.12.2024
gilead appoints dietmar berger as new chief medical officer from sanofi
Gilead Sciences has appointed Dietmar Berger, M.D., Ph.D., as its new chief medical officer, recruiting him from Sanofi to replace Merdad Parsey. Berger, a cancer specialist with extensive experience at Genentech and Sanofi, will oversee Gilead's oncology pipeline, which is crucial for the company's growth strategy. He is set to start on January 2, 2024, as Gilead aims to enhance its oncology business amid significant clinical developments.
Fierce Biotech
United States Dollar Hoffmann-La Roche AG Gilead Sciences, Inc. Bayer AG Immunomedics Inc. Genentech Amgen Inc. Sanofi USA FRA John S. Reed Houman Ashrafian Daniel O'Day Merdad Parsey Dietmar Berger Show more
Healthcare, News Article
11:20 13.12.2024
icER highlights unsupported price hikes by major pharmaceutical companies
ICER's annual report criticizes major pharmaceutical companies, including Gilead, J&J, and Novartis, for "unsupported" price increases on ten drugs, leading to an additional $815 million in U.S. payer costs last year. Gilead's Biktarvy topped the list with a 5.9% hike, costing $359 million. Companies have pushed back, claiming ICER's methodology overlooks crucial clinical evidence and could hinder the development of new treatments.
Fierce Pharma
United States Dollar Johnson & Johnson Exelixis, Inc. Gilead Sciences, Inc. Pfizer Inc. Novartis AG USA Show more
Regulatory & Legal, Press Release
20:24 12.12.2024
gilead sciences receives mixed analyst ratings and insider selling raises concerns
Gilead Sciences has received several price target increases from analysts, with Oppenheimer and JPMorgan raising their targets to $105, while BMO Capital Markets set theirs at $102. Despite a "Moderate Buy" rating, top analysts favor five other stocks over Gilead. Insider trading activity shows significant sales, with insiders offloading over 63,000 shares in the past ninety days.
MarketBeat
Gilead Sciences, Inc. USA Johanna Mercier Jeffrey Bluestone Show more
TradFi, Market Report
14:22 28.11.2024
Gilead Sciences reports strong pharmaceutical sales driven by HIV and COVID-19 treatments
Gilead Sciences, Inc. focuses on developing, manufacturing, and marketing therapeutic products, with 98.9% of net sales coming from pharmaceuticals. Key revenue sources include treatments for HIV (63%), COVID-19 (20.4%), and hepatitis viruses. Geographically, 69.2% of sales are in the U.S., followed by Europe (16.4%) and other regions (14.4%).
MarketScreener
Euro United States Dollar Gilead Sciences, Inc. USA
TradFi, Market Report
21:07 22.11.2024
rth america oncology drugs market projected to reach 27.20 billion by 2033
The North America oncology drugs market, valued at USD 10.13 billion in 2023, is projected to grow at a CAGR of 10.38%, reaching USD 27.20 billion by 2033. Key drivers include advances in cancer research, rising cancer prevalence, and increasing demand for personalized medicine, while challenges include high drug costs and stringent regulations. The market is segmented into cytotoxic, targeted, and hormonal drugs, with targeted therapies expected to dominate due to their effectiveness and reduced toxicity.
Spherical Insights
United States Dollar Novartis AG Gilead Sciences, Inc. Sanofi Takeda Pharmaceutical Company Limited Johnson & Johnson Amgen Inc. Bristol-Myers Squibb Company Biogen Inc. AstraZeneca PLC Roche Holding AG Pfizer Inc. Merck & Co., Inc. Celgene Corporation AbbVie Inc. Eli Lilly and Company USA Show more
Healthcare, Market Report
14:29 22.11.2024
corporate borrowing surges as us bond market reacts to election results
Corporate borrowers are seizing the opportunity in the US bond market, raising over $50 billion this week, driven by favorable conditions following Donald Trump's election victory. With corporate borrowing costs at their lowest in decades, companies are accelerating bond issuance, particularly in the financial sector. The surge in stock prices has also led to increased activity in equity capital markets, with private equity firms raising about $6 billion through follow-on sales since the election.
@FinancialTimes
United States Dollar Gilead Sciences, Inc. Boeing Caterpillar Inc. The Goldman Sachs Group, Inc. USA John McAuley Teddy Hodgson Show more
Finance & Economy, Market Report
06:00 15.11.2024
global healthcare services market poised for significant growth through 2028
The global healthcare services market is projected to grow from $8,348.44 billion in 2023 to $8,963.64 billion in 2024, driven by advancements in medical technology, an aging population, and health insurance expansion. By 2028, it is expected to reach $10,908.99 billion, with key trends including telemedicine integration and patient-centered care. Shared medical appointments are gaining traction as a cost-effective model for managing chronic conditions, enhancing patient outcomes through collaborative care.
openPR.com
United States Dollar Community Health Systems, Inc. UnitedHealth Group Incorporated CVS Health Corporation Regeneron Pharmaceuticals, Inc. Cardinal Health, Inc. Fresenius Medical Care AG & Co. KGaA Centene Corporation Baxter International Inc. Mayo Clinic Agilent Technologies, Inc. Johnson & Johnson Pfizer Inc. Cleveland Clinic Global Solutions LLC McKesson Corporation Merck & Co., Inc. Abbott Laboratories Bristol-Myers Squibb Company Quest Diagnostics Incorporated HCA Healthcare, Inc. Gilead Sciences, Inc. Kaiser Permanente Group Trust Cigna Corporation Stryker Corporation Tenet Healthcare Corporation Danaher Corporation AbbVie Inc. Boston Scientific Corporation Molina Healthcare, Inc. Align Technology, Inc. AmerisourceBergen Corporation Laboratory Corporation OF America Holdings DaVita Inc. Eli Lilly and Company Humana Inc. West Pharmaceutical Services, Inc. Fresenius Medical Care AG & Co. KGaA Kaiser Permanente UnitedHealth Group Incorporated Tenet Healthcare HCA Healthcare Show more
Healthcare, Market Report
20:40 11.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Corporate Responsibility & ESG Market Sentiment Analysis Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Banking Regulations Tokenomics and Crypto Economics Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD Credit Suisse Real Estate Fund Siat NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Karin Keller-Sutter Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Ueli Maurer Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.